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Abstract 
The main aim of this study was to estimate the costs associated with diagnostic assessment and 1-year therapy in 
children and adolescents enrolled in 18 ADHD reference centres. Data concerning 1887 children and adolescents 
from the mandatory ADHD registry database during the 2012–2014 period were analysed. The overall diagnostic and 
treatment costs per patient amounts to €574 and €830, respectively. The ADHD centre, the school as sender, and the 
time to diagnosis constitute cost drivers. Non-pharmacological therapy resulted as being more expensive for patients 
concomitantly treated with drugs (€929) compared to those treated with psychological interventions alone (€590; 
p = 0.006). This study gives the first and reliable estimate of the costs associated with both diagnosis and treatment of 
ADHD in Italy. Although costs associated with mental disorders are difficult to estimate, continuing efforts are need to 
define costs and resources to guarantee appropriate care, also for ADHD.
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Background
The costs of psychiatric disorders have been scantly 
investigated, particularly with regard to those that affect 
children and adolescents [1, 2]. Methodological complex-
ities justified the lack of comprehensive estimates of the 
economic impact associated with the burden of psychiat-
ric disorders [3, 4]. World-wide up to 20% of children and 
adolescents suffer from a neuro-psychiatric condition; in 
developed countries, both mental and neurological disor-
ders account for the 40% of the burden of all brain dis-
eases and for the 35% in Europe only [5–8].
Attention deficit hyperactivity disorder (ADHD) is a 
neurobiological disorder [9] characterized mainly by clin-
ical manifestations such as difficulty in paying attention, 
impulsive behaviour, and a heightened level of physical 
activity, occurring more frequently and intensely than 
in other children of the same age or developmental level 
[10]. ADHD symptoms usually become more evident 
in school aged children, are more frequent in boys than 
girls (ratio 3:1), and tend to persist into adulthood [11]. 
ADHD accounts as the third most common mental dis-
orders in children and adolescents [12].
Despite a pooled worldwide ADHD prevalence in 
children and adolescents of 5.3%, there is wide variabil-
ity between and within countries [13]. Such variability 
in prevalence rates may be explained by the different 
methodologies, diagnostic procedures, and criteria used 
in the studies [14, 15] as well as by the different settings 
and cultural approaches considered [16, 17]. However, 
when standardized diagnostic and impairment assess-
ment procedures are followed, prevalence does not 
seem to have changed over time nor to have differed in 
the geographic locations considered [18]. According to 
national and international guidelines [19–22], ADHD 
treatment should be based on a multimodal approach 
combining psychosocial interventions with pharmaco-
logical therapies, and should take into consideration the 
subject’s characteristics, including age, symptom severity, 
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co-morbid disorders, cognitive level, and social and fam-
ily context.
The impairments of ADHD are multi-faceted and occur 
in multiple settings, as costs associated with ADHD 
impact multiple societal costs within and outside the 
healthcare sector [23, 24]. Studies on the economic bur-
den of ADHD within Italy, where healthcare is provided 
to all citizens, are currently lacking [25, 26]. An under-
standing of the costs associated with ADHD in children 
and adolescents is important for public policy makers as 
a rationale for improving and planning public services for 
both diagnosis and treatment [27].
Overall, in addition to the human suffering they cause, 
psychiatric disorders are among the most expensive of 
all health problems in adults [24, 28], even if evidence 
regarding the costs of psychiatric disorders has been 
slow to accumulate, particularly with regard to those that 
affect children and adolescents [29]. Literature review of 
the health care and treatment-related ADHD economic 
impact estimates an annual cost, specifically for children 
and adolescents, at $14,576 per individual, with a com-
prehensive range from $36 billion to $52.4 billion con-
sidering an ADHD prevalence rate of 5% [30]. However, 
these estimates are incomplete and inaccurate due to the 
fact that the majority of the existing studies did not fully 
assess all the potential costs related to an ADHD diag-
nosis [31]. A few reviews covering the attempts made 
at defining economic impact of ADHD by the limited 
number of available, country-based studies, highlighted 
a wide range in the magnitude of the societal cost esti-
mates [30, 32–38].
In June 2011 an official ADHD regional registry was 
activated in the Lombardy Region, designed as a dis-
ease oriented registry collecting information on all sub-
jects who access ADHD centres for a suspected ADHD 
diagnosis [39–41], as part of a regional project aimed 
to define a common approach to, and improve, ADHD 
diagnosis and therapy. In the Lombardy Region, during 
the study period, a network of 34 Child and Adolescent 
Neuropsychiatric Services (CANPS) provide care at the 
hospital (tier three) and community (tier two) levels for 
children and adolescents with neurologic, neuropsycho-
logic and/or psychiatric disorders, and for their families. 
About 15% of the Italian pediatric population live in this 
region. Regional health authorities are responsible for the 
accreditation of the ADHD reference centers in regional 
hospitals (“ADHD centers”), as specialized ADHD hubs 
(tier three) of the CANPS network.
In such a context, the objective of this study was to esti-
mate the costs, from the National Health Service (NHS) 
perspective, associated with diagnostic assessment 
and 1-year therapy in children and adolescents aged 
5–17  years enrolled in any of the 18 ADHD reference 
centres of the Lombardy Region between January 2012 
and December 2014 for suspected ADHD.
Methods
This study was designed as a review of patient medical 
records identified from the Regional ADHD Registry 
database, to estimate the costs of the diagnostic assess-
ment and 1-year therapy for subjects with a suspected 
ADHD diagnosis. The research was approved by the 
Institutional Review Board of the IRCCS—Istituto di 
Ricerche Farmacologiche “Mario Negri” Milan, Italy. 
Written informed consent was obtained for all patients 
to put information in the registry database and analyze 
them anonymously.
Setting
This study is part of a specific project supported by the 
Regional Health Ministry and aimed to ensure appro-
priate ADHD management for every child and adoles-
cent once the disorder is suspected and reported, and 
includes commonly acknowledged diagnostic and thera-
peutic procedures as well as educational initiatives for 
health care workers (child psychiatrists and psycholo-
gists) of the Lombardy Region’s health care system. The 
project’s participants are all the 18 ADHD centres of the 
Lombardy Region, the most economically important and 
populated Italian region with 1.690.127 citizens under 
18 years old, and with an average income earned per per-
son equal to € 24.005 in the study period. The ADHD 
centres, accredited by regional health authorities, are the 
hubs specialised in ADHD (Tier 3) of the Child and Ado-
lescent Neuropsychiatric Services (CANPS) network and 
provide diagnosis and treatment care free, or at a nomi-
nal charge, working mainly on an outpatient basis and 
in close connection with educational and social services. 
ADHD centres are also responsible for the prescrip-
tion of pharmacological therapies and their monitoring 
over time. Moreover, ADHD centres are responsible for 
inputting data into the official ADHD registry and for 
providing parent, teacher, and child training treatments 
[39–41].
Study population and pathways of care
Anonymized, updated data of the official ADHD regis-
try of the Lombardy Region (as of 31 August 2015) were 
available, with 3163 subjects enrolled in the June 2011–
August 2015 period. The study population includes chil-
dren and adolescents from January 2012 to December 
2014 who had both a first outpatient visit at one of the 
18 ADHD centres for a suspected ADHD diagnosis in the 
same period and had a complete diagnostic evaluation 
and treatment prescription at the time of data extraction. 
Our goal was to identify only children who had never 
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been evaluated and treated before for ADHD. We further 
required that all of the study children with a confirmed 
ADHD diagnosis were received a care continuity at the 
ADHD centre within a 1-year period.
The guideline for all clinicians at the ADHD centres 
is to use the Diagnostic and Statistical Manual of Men-
tal Disorders, Fourth Edition [42] criteria for diagnosing 
ADHD. Moreover, to define an optimal, evidence-based, 
shared strategy for diagnostic evaluation, an ad hoc 
assessment working group was created, involving a child 
neuropsychiatrist and a psychologist from each partici-
pating ADHD center and a group of researchers of the 
registry coordinating center (IRCCS—Istituto di Ricerche 
Farmacologiche “Mario Negri”). More specifically, also 
according to the recommendations of the Italian guide-
lines [22, 43], this strategy consisted of seven mandatory 
steps to be applied at the time of diagnostic evaluation: 
(1) a clinical anamnestic and psychiatric interview; (2) 
the neurological examination; (3) the evaluation of cog-
nitive level by Wechsler Scales [44]; (4) the Schedule for 
Affective Disorders and Schizophrenia for School-Age 
Children (K-SADS) [45] for a complete psychopathol-
ogy overview and comorbidity assessment; (5) the Child 
Behavior Checklist (CBCL) and/or the Conners’ Parent 
Rating Scale–Revised (CPRS-R) rated by parents; (6) the 
Conners’ Teacher Rating Scale–Revised (CTRS-R) rated 
by teachers; [46–48] and (7) the Clinical Global Impres-
sions-Severity scale (CGI-S) [49] to quantify symp-
tom severity. This diagnostic pathway was agreed on, 
approved, and shared by all participating ADHD centers.
Once a patient receives a diagnosis of ADHD and a 
treatment prescription, the registry is designed to provide 
differently structured types of follow-up visits at periodic 
intervals: at 3 and 6 months after the diagnosis, and every 
6 months afterward for all patients; while for those given 
methylphenidate at 1 week and 1 month after the diagno-
sis also (after only 1 month if they received atomoxetine 
or other psychotropic drugs). Moreover, patients that 
receive a methylphenidate prescription need to perform a 
visit called “dose-test” which is carried out in day hospital 
regimen before starting the drug treatment.
Data analytic procedures
Complete data of all eligible patients were extracted. 
Besides anamnestic and clinical information regarding 
age, gender, diagnosis and comorbidity, detailed informa-
tion was available on a patient medical records basis for 
the following cost domains:
  • Diagnostic pathway: all services supplied to patients 
with a suspected ADHD diagnosis, whether or not 
confirmed, by an agreed and shared child and ado-
lescent neuropsychiatrists’ and psychologists’ assess-
ment. In addition, the working days elapsed from 
the request a diagnosis of ADHD were calculated. 
In line with the regional health service perspective, 
only direct healthcare costs were estimated. Unit 
costs related to diagnostic tests were derived from 
tariffs reimbursed by the Lombardy Region in 2014. 
Detailed information is presented in Additional file 1: 
Table S1.
  • Non-pharmacological therapies: Prescribed by phy-
sicians specialised in child and adolescent neuropsy-
chiatry working in one of the 18 ADHD centres and 
provided by other therapists for example psycholo-
gists, also working within the ADHD centre. The 
direct health cost of non-pharmacological therapies 
was assessed by multiplying the estimated number 
of annual visits per patient by the unit costs derived 
from tariffs reimbursed by the Lombardy Region in 
2014. Detailed information is presented in Additional 
file 1: Table S2.
  • Pharmacological treatments: Prescribed by medical 
doctors specialised in child and adolescent neuropsy-
chiatry working in one of the 18 ADHD centres (only 
prescriptions filled by patients). Drug utilization data 
were also derived from the Regional ADHD registry 
[39, 40]. Detailed information is presented in Addi-
tional file 1: Table S3.
Data on the total annual consumption of ADHD medi-
cations that require a therapeutic plan prescription form 
were evaluated over 1 year after the date of the diagnosis. 
The trends in total consumption of ADHD drugs were 
also analysed based on changing patterns of the drugs’ 
prescription practices, dosages, and formulations.
The unit costs of prescribed drugs were assessed based 
on: (a) price to public of medicines fully reimbursed by 
the Italian NHS and supplied through retail pharmacies 
(class A); or (b) sum of ex-factory price and 10.2% dis-
tribution margin of fully reimbursed drugs under direct 
distribution. Patient co-payment was not considered as it 
impacted a minority (<10%) of patients under drug treat-
ment. The cost per milligram was calculated on the basis 
of the prescribed formulation (immediate- or extended-
release, tablet, capsule, drops) by selecting the generic, 
when marketed. Annual drug consumption was estimated 
for each patient by multiplying the daily dosage prescribed 
at each visit by the number days until the following visit.
Laboratory tests,—including blood count, blood sugar, 
haemoglobin, ferritin, albumin, bilirubin, transaminases, 
gamma-glutamyl transpeptidase, erythrocyte sedimen-
tation rate, thyroid hormones, uric acid, BUN, creati-
nine, urine—and EKG were carried out in day hospital 
(DH) setting only in patients undergoing pharmacologi-
cal treatments, according to the Italian guidelines [22]. 
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Hence, they were considered as pharmacological treat-
ment-related expenditures. A DH unit cost of €232.00 was 
derived from DRG code 431 reimbursed by the Lombardy 
Region in 2014. Hospitalization (inpatient regimen) costs 
were been estimated as no patient was hospitalized.
All data were analysed with SAS Version 9.2, (SAS Insti-
tute, Inc., Cary, NC, USA). Descriptive statistics were com-
puted for the entire study population and for subgroups. 
As costs of diagnostic pathways (recommended, optional, 
and total), time to diagnosis, and treatment costs were not 
normally distributed, median and inter quartile ranges 
were analysed. The Student’s t test was used to compare 
continuous variables (baseline clinical and anamnestic 
data), while χ2 (baseline clinical and anamnestic data), 
Wilcoxon–Mann–Whitney (diagnosis related costs, time 
to diagnosis evaluation), and Kruskal–Wallis (treatment 
and diagnosis related costs) tests were used to compare 
categorical variables. A multivariate logistic regression 
analysis with stepwise selection was carried out to assess 
the socio-demographic (baseline personnel and familiar 
data) and clinical, service models’ characteristics (clinical 
and organizational determinants). Moreover, a multivari-
ate linear regression analysis was performed to assess the 
drivers of diagnostic costs and time to diagnosis.
Results
Baseline characteristics
Data concerning 1887 children and adolescents who 
accessed 1 of the 18 ADHD centres for the first time 
during the 2011–2015 period and. completed the diag-
nostic evaluation at the time of data extraction (Septem-
ber 1, 2015; Table  1) were analysed. These patients had 
a median age of 9 years (range: 5–17 years) at their first 
visit, and 1597 (85%) were males and 290 (15%) were 
females. In all, 1276 patients (68%) met DSM-IV-TR cri-
teria (43) for ADHD: 1099 (86%) males and 177 (14%) 
females. In all, 1189 of 1887 (63%) enrolled patients had 
one or more psychiatric disorders (346 without ADHD) 
(learning disorders, 56%; sleep disorders, 19%; anxiety 
and mood disorders, 19%; oppositional defiant disorder, 
17%; other, 13%), whereas 163 (9%) had a concomitant 
chronic diseases (neurological, 31%; respiratory, 30%; 
gastrointestinal, 7%; other, 19%). As shown in Table 1, the 
main anamnestic characteristics significantly associated 
with ADHD diagnosis were: lower age, presence of sup-
port teacher (at the time of assessment), ADHD familiar-
ity, and an associated psychiatric disorder.
Diagnosis related costs
Total diagnostic cost per patient to complete the diag-
nostic evaluation amounted to €574.00, of which €510.00 
was related to recommended procedures and tests and 
€105.60 to optional examinations (Fig.  1; Additional 
file 1: Table 4). The multivariate analysis highlighted the 
following cost drivers: ADHD centre, sender, and time to 
diagnosis (Table  2). Concomitant psychiatric disorders, 
as well as other clinical and anamnestic variables, didn’t 
affect diagnosis costs (Table 2).
Statistically significant (Kruskal–Wallis, p  <  0.001) 
inter-centre variability was related to the completion 
rate of the recommended set of assessments (Additional 
file 1: Table S5). The total cost of the diagnosis also var-
ied in relation to the sender and was highest for patients 
referred from CANPS (€615.60). However, the relative 
increase was only 7.4% over the total median cost (Addi-
tional file 1: Table S6).
Globally, it took 119  days to complete the diagnostic 
pathway, with a wide variability mainly due to the centres 
(range from 51 to 302 days; Kruskal–Wallis, p < 0.0001) 
and the senders, with median time-to-diagnosis mark-
edly reduced when the patient was referred by CANPS 
(91  days) or increased if referred by GPs (162  days), or 
by other specialist neuropsychiatrists practicing in 
agreement with the NHS (169.5  days; Kruskal–Wallis, 
p < 0.0001; Additional file 1: Table S7.
Whether or not the diagnosis of ADHD was confirmed 
on elapsed time was not statistical significative: 123 days 
if positive compared to 108 days if negative (Wilcoxon–
Mann–Whitney, p = 0.0871). However, the time to diag-
nosis was slightly greater for patients receiving all the 
recommended tests (122 working days) compared to 
those who did not complete the assessment (111.5 days; 
Wilcoxon–Mann–Whitney, p = 0.0086).
Assuming that the time to diagnosis could be consid-
ered as a measure of efficiency by the regional health 
service (and by patients, too), Fig. 2 shows the wide varia-
bility among centres of the ratio of costs reimbursed by the 
health service and median time to diagnosis. This ratio var-
ies significantly also in relation to the sending unit (Fig. 3).
Treatment costs
The following annual treatment costs were assessed for 
patients with an ADHD diagnosis (n = 753):
  • Non-pharmacological interventions: 1092 patients 
(86%), of whom 903 received a non-pharmacological 
intervention only (71%) and 189 (15%) combined 
with drugs;
  • Drug treatments: 199 patients (16%), of whom 10 
(1%) received drug treatment alone and 189 (90%) 
combined with non-pharmacological treatments.
The remaining 174 patients (14%) were not included 
because they were still being monitored (watchful-wait-
ing) at the time of data extraction. Detailed information 
is presented in Additional file.
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The median total treatment cost per patient, including 
laboratory and instrumental assessment needed to begin 
the drug therapy, was €830.00 (Additional file  1: Table 
S8), and resulted due mainly to the non-pharmacological 
therapy cost per patient. In addition to marked variability 
among centres (Kruskal–Wallis, p  <  0.0001; Additional 
file 1: Table S9), non-pharmacological therapy resulted as 
being more expensive for patients concomitantly treated 
with drugs (€929) compared to those treated with psy-
chological interventions alone (€590; Wilcoxon–Mann–
Whitney p = 0.0064).
Pharmacological treatments were prescribed in 14 
out of 18 centres. Methylphenidate was the most used 
drug, prescribed in 170 patients (85.4%), followed by 
atomoxetine (10.1%). Median drug cost for 1 year was 
€97.60, of which €65.36 covered by stimulant treatment 
and €32.34 by non-stimulant treatment. Inter-centre var-
iability (Fig. 4) was not statistically significant (Additional 
file 1: Table S10).
A total of 331 adverse events associated with drug 
treatments were reported, of which 9 (3%), 99 (30%), and 
222 (67%) were classified as severe, moderate and mild, 
respectively. No action was required for 208 adverse 
events, while, for the remaining events, patients recov-
ered upon drug discontinuation (n  =  77, 23%) or dose 
changing (n = 46, 14%). No patient was treated or hos-
pitalised due to adverse events so no adjunctive cost esti-
mation was needed.
Table 1 Demographic and clinical characteristics of the sample population
* t test for continuous and χ2 for categorical variables
Characteristics Total sample (N = 1887) With ADHD (n = 1276) Without ADHD (n = 611) p*
Age M (SD); median 9.3 (2.5); 9 9.1 (2.4); 9 9.7 (2.5); 9 <0.0001
 5–11, n (%) 1506 (80) 1038 (81) 468 (77) 0.0161
 12–17, n (%) 381 (20) 238 (19) 143 (23)
Male: female 1597:290 1099:177 498:113 0.0092
Only child, n (%) 453 (24) 328 (26) 125 (20) 0.0116
Born abroad, n (%) 99 (5) 76 (6) 23 (4) 0.0453
Adopted, n (%) 63 (3) 54 (4) 9 (1) 0.0018
School variables, n (%)
 Grade
  Primary 1417 (75) 980 (77) 437 (72) 0.0139
  Middle 465 (25) 293 (23) 172 (28)
  Repeaters 99 (5) 61 (5) 38 (6) ns
  Support teacher 142 (8) 123 (10) 19 (3) <0.0001
Parent/family variables, n (%)
 High school graduate
  Mother 1070 (64) 694 (63) 376 (66) ns
  Father 871 (53) 562 (52) 309 (55) ns
  Employed
  Mother 1235 (72) 840 (74) 395 (67) 0.0028
  Father 1584 (95) 1046 (95) 538 (94) ns
  Family history of ADHD 375 (20) 293 (23) 82 (13) <0.0001
Anamnestic data, n (%)
 Pregnancy
  Cesarean section 465 (26) 333 (28) 132 (23) 0.0207
  Preterm (<37 weeks) 168 (9) 120 (10) 48 (8) ns
  Low weight (<2500 g) 149 (9) 107 (9) 42 (7) ns
  Motor delay 85 (5) 60 (5) 25 (4) ns
  Language delay 366 (20) 266 (22) 100 (17) 0.0167
Psychiatric disorders, n (%)
 One or more 1189 (63) 843 (66) 346 (57) <0.0001
Other chronic medical conditions, n (%)
 One or more 163 (9) 110 (9) 53 (9) ns
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Fig. 1 Total diagnostic cost (€) per patient: intercenter variability
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Discussion
This study presents the first, and most comprehensive, 
estimate to date of the costs, from the NHS perspec-
tive, associated with both the diagnostic assessment and 
a 12-month therapy in children and adolescents with 
ADHD in Italy. The overall diagnostic and treatment 
costs per patient amounts to €574 and €830, respectively 
(median total: €1404). In our opinion, this is a reliable 
and representative estimate of ADHD health costs in 
Italy. Indeed, in our country, the management of ADHD 
patients was provided mainly by a network of specialized 
hubs on ADHD (Tier 3)—the Regional ADHD centres—
who are responsible for following the most appropri-
ate diagnostic procedures and treatment prescriptions 
according to the Italian guidelines [22, 43]. This process, 
in the Lombardy Region, was strictly monitored by the 
official Regional ADHD registry [40, 41] thus we can 
therefore expect that it accurately represents a cost esti-
mate that is consistent with that of the management of 
ADHD in real clinical practice. The evaluation of ADHD 
costs presented in this article was calculated through 
a retrospective analysis of data inputted in this registry. 
Moreover, neuropsychiatrists working at the ADHD cen-
tres are also the only clinicians who, according to exist-
ing Italian legislation, can prescribe drug therapies for 
ADHD. This, in turn, gave us the possibility of calculating 
a reliable estimate also of the total treatment costs.
These costs are consistent, in some cases, and not, in 
others, with those previously suggested in other countries 
[32, 35, 50–56]. Such variability in ADHD costs reported 
may be explained by the different methodologies, espe-
cially diagnostic procedures, and criteria used in the stud-
ies, as well as by the different settings considered, and, 
for some authors, also the different cultural approaches 
[17]. In particular, psychopharmacological treatment 
in Italian children and adolescents is not the norm, and 
prescription rates for mental disorders are relatively low. 
A recent Italian study [40] shows that only 16% of ADHD 
patients are treated pharmacologically, compared with 
higher rates reported in other countries, suggesting that 
also for ADHD, the cultural education and disposition, 
and the professional attitude of the majority of the child 
Table 2 Drivers of the diagnostic costs: multivariate analyses
Constant Coefficient CI 95% p*
378.55 (348.43–408.66) <0.0001
Center
 A 66.24 (48.05–84.42) <0.0001
 B 20.25 (2.42–38.08) 0.0260
 C 77.75 (59.81–95.69) <0.0001
 D 51.21 (30.99–71.42) <0.0001
 E 70.33 (48.53–92.12) <0.0001
 F 79.40 (58.18–100.62) <0.0001
 G 75.76 (55.44–96.108) <0.0001
 H 72.11 (54.92–89.31) <0.0001
 I 79.72 (58.63–100.8) <0.0001
 J 93.36 (75.5–111.22) <0.0001
 K 38.67 (15.63–61.71) 0.0010
 L –
 M 87.82 (13.78–161.86) 0.0201
 N 46.85 (25.86–67.84) <0.0001
 O 84.22 (67.35–101.09) <0.0001
 P 82.20 (61.25–103.15) <0.0001
 Q 59.44 (32.61–86.28) <0.0001
 R 77.65 (56.14–99.15) <0.0001
Gender
 Female 4.41 (−2.79 to 11.61) ns
 Male –
Age at diagnosis
 Years 0.70 (−1.14 to 2.54) ns
Scholarship
 Primary 6.71 (−3.66 to 17.08) ns
 Middle –
Scholar support
 Yes –
 None 9.56 (−0.84 to 19.97) ns
Sender
 GP 8.70 (−5.78 to 23.19) ns
 Relatives –
 School 9.47 (1.52–17.43) 0.0196
 Neuropsychiatric 
(private)
5.38 (−5.89 to 16.65) ns
 Neuropsychiatric 
(NHS)
5.65 (−8.08 to 19.38) ns
 CANS 5.11 (−3.77 to 14) ns
Familiar history of ADHD
 Positive 2.10 (−4.99 to 9.18) ns
 Negative –
Diagnosis of ADHD
 Yes 2.70 (−3.55 to 8.94) ns
 None –
Psychiatric concomitant disorders
 Yes –
 None 0.66 (−5.02 to 6.33) ns
Table 2 continued
Constant Coefficient CI 95% p*
378.55 (348.43–408.66) <0.0001
CGIS
 <5 3.74 (−3.15 to 10.64) ns
 ≥5 –
Time to diagnosis
 Working days 0.05 (0.02–0.09) 0.0033
* Multivariate linear regression model
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psychiatrists of the Lombardy Region’s mental health ser-
vices, are more inclined toward behavioural treatments 
than the use of drugs. To date, a cost analysis on ADHD 
in Italy has not yet been performed and published. An 
abstract presented in a conference contribution shows 
similar costs compared to those estimated in the present 
study [25]. This study, however, was methodologically 
different and did not calculate the diagnostic versus the 
therapeutic costs separately, and this does not allow us to 
make a more critical comparison with our findings.
Our cost analysis is relevant from the perspective of the 
Italian NHS not only for ADHD [27]. Indeed, the ADHD 
centre, the sender, and the time to diagnosis, but not the 
ADHD diagnosis itself, constitute cost drivers. We can 
thus expect these drivers to be common to other men-
tal health disorders. Moreover, assuming that the time 
to diagnosis is a moderator measure of care efficiency, 
and considering the wide inter-centre variability in both 
the relationship between cost and time to diagnosis, and 
between cost and diagnosis completeness according to the 
National recommended guidelines, these data could serve 
as a measure for monitoring and reassessing the accredi-
tation over time of the 18 regional centres as specialized 
hubs on ADHD.
Interestingly, when community CANPS (Tier 2) was the 
sender, time to diagnosis markedly decreased (1 month), 
with a relative increase (7%) over the total cost. As such, 
the recommended pathway of care by the Italian National 
Institute of Health (Istituto Superiore di Sanità, ISS) 
[57] when a child has a suspected diagnosis of ADHD 
states that the paediatrician should refer the child to the 
CANPS, and that the CANPS, after a psychiatric screen-
ing assessment (if necessary) should refer the patient to 
the ADHD centre (Tier 3). Our findings confirm that this 
suggested model of transition of care is likely to be a pos-
itive, cost-effective pathway, given that it ensures a more 
prompt response to care needs in exchange for an accept-
able increase of direct health costs.
There is public concern that the more rapid efficacy, in 
symptomatic terms, of pharmacological therapy, com-
bined with its lower cost compared to non-pharmacolog-
ical interventions, could favour an increased use of drugs 
Fig. 2 Median time to diagnosis (working days) and diagnostic costs (€): Intercenter variability. Bubbles’ size represents the number of diagnoses 
per center
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alone for the ADHD management [58]. As previously 
reported [16, 39, 40] this study showed a significantly 
higher prescription of non-pharmacological treatments, 
thus confirming that this alarming risk is absolutely not 
present in the Italian context. Indeed, the majority of the 
children with ADHD were not currently receiving medi-
cation. This is due, in part, to an Italian tradition that 
drug treatment should be reserved for those with more 
severe symptoms and impairments [59]. To some extent, 
the modest incremental cost of the combination of drug 
and behavioural interventions, compared to behaviour 
therapies alone resulting in the present study, represent-
ing for more effective, versus less effective, management 
strategies, as widely suggested, should be considered in 
terms of the best choice for each patient.
Moreover, it has also become apparent from our analy-
sis that the cost of the non-pharmacological therapies is 
higher whether these are combined with drug treatment. 
This finding is probably related to the fact that patients 
requiring a combined treatment more often present 
greater severity in terms of both symptomatology and 
functional impairment. We can thus expect that, for 
these patients, not only is a more intensive (in terms of 
frequency) psychoeducational approach needed, but 
there is also a need that this approach be carried out in 
several different settings in the children’s life [58].
Finally, the ADHD project of the Lombardy Region 
ensured that the diagnostic and therapeutic protocol fol-
lowed by the ADHD centres, on which the cost analysis 
was based, was strictly monitored by the official registry, 
that it has been established according to the main recom-
mendations of the national guidelines and that it is repre-
sentative of the real clinical practice of an entire region. 
Indeed, the compliance to the shared diagnostic and 
therapeutic evaluation, according to the project guide-
lines, estimated by the analysis of data recorded by all 
18 ADHD centers is very high and homogeneous in the 
Regional context (total completeness: 93.6%; range: 81.7–
99.1%). We can’t expect similar conclusions assuming to 
analyze ADHD health care differences and similarities 
between the Italian regions: various socioeconomic and 
service organization characteristics, i.e., may be explain 
Fig. 3 Median time to diagnosis (working days) and diagnostic costs (€): Variability by types of the senders. Bubbles’ size represents the number of 
diagnoses per sender; CANS Child and Adolescent Neuropsychiatry Service, GP General practitioner. Asterisk specialist neuropsychiatrists practicing 
in agreement with the NHS
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Fig. 4 Total treatment cost (€) per patient: intercenter variability
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a part of these differences and highlighting an important 
and broader issue, but not specific to the ADHD man-
agement. Limited literature data available from the Ital-
ian context are not enough to reach useful comparisons 
and comments about regional differences among ADHD 
management.
However, the Regional ADHD Registry, as the main 
tool to monitor the ADHD project, was designed as a dis-
ease-oriented registry collecting information not only on 
ADHD patients treated with pharmacological therapy (as 
provided by the National Registry) but also on all patients 
who access ADHD centers for a diagnosis of suspected 
ADHD.
These reasons strengthen the potential use of our find-
ings as a proxy model to estimate the cost of the imple-
mentation of the guidelines in clinical practice for the 
development of similar projects in other Italian regions 
or for other mental health disorders.
Limitations
A few study limitations should be mentioned. First, our 
estimate was based on tariffs reimbursed by the Regional 
Health Service that does reflect the direct medical costs 
and not all costs of care provided. Furthermore, the esti-
mates did not include other perspectives considered in 
cost studies, such as societal and caregiver perspectives. 
Subjects with mental health problems, including ADHD 
patients, require support from several dimensions in 
life, not only from the healthcare system, i.e. social care, 
housing, and employment [27, 60]. Service utilization, 
outpatient care, and medications, however, are described 
as the main components of the economic impact of 
a disorder in mental health [3]. Second, although the 
Lombardy Region is the most populated region in Italy, 
representing about 17% of the national health care costs, 
all data originated from a single region of Italy, and this 
may affect the generalizability and comparability of the 
reported findings. However, studies evaluating costs of 
mental health problems are not easily generalisable from 
one country to another because service systems, fund-
ing arrangements, and relative prices can vary consider-
ably. Third, the clinical effect of the treatments was not 
explored. It was therefore not possible to perform a cost-
effectiveness evaluation, although, to our knowledge, this 
is the first study that estimates the ADHD costs for both 
diagnosis and therapeutic pathways, with previous stud-
ies typically focusing only on economic evaluation of the 
treatment.
Implications for behavioral health
This study gives a reliable indication of the economic 
effect of both diagnosis and treatment of ADHD in 
Italy from the NHS perspective. There is clearly a need, 
however, for a comprehensive picture of the total health 
and societal costs of ADHD. There also is an urgent need 
for studies on cost-effectiveness of interventions and for 
consequent support arrangements for specialised ADHD 
services that address the needs of patients and their fami-
lies so as geographically equitable and efficient as to the 
best evidence care management.
The costs associated with mental disorders are difficult 
to estimate, but continuing efforts to do so increase avail-
able evidence as well as the understanding of the strug-
gles of the individuals and families who need appropriate 
and adequate care.
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